#LB0005 #EULAR2022 Phase 1B/2A dose-ranging RCT of Orelabrutinib, a BTK-inhibitor showed BTK occupancy in all doses in #lupus. SRI-4 response was higher in all doses vs PBO. Effects were better in SLEDAI=>8. Well tolerated & no major safety. Promising early data @RheumNow https://t.co/vJBLRQgYBP

Tofacitinib had faster and larger impact on improvement of fatigue compared to placebo in treatment of ankylosing spondylitis pts. Note 100% fatigue resolution roughly same vs. placebo @RheumNow #EULAR2022 ABST#POS0305 https://t.co/Doep91QIRa

#EULAR2022 LB0005 Orelabrutinib- BTKi- for SLE, PIb/IIa ⭐️Improved SRI-4 and SLEDAI-2K vs PBO, dose response for SRI-4 ⭐️Improved proteinuria @Rheumnow https://t.co/bmREhmL7sq

SAPHYR trial of sarilumab for relapsing PMR @profbdasgupta et al. Sarilumab+14 week steroids vs 52 week steroid monotherapy. Sustained remission 28.3% vs 10.3% P=0.0193. Flare after remission 16.7% vs 29.3% HR 0.56 (0.35–0.90) P=0.0158 @RheumNow #EULAR2022 https://t.co/oopWKjciWG https://t.co/xi4ELJiCXa

• EULAR Abstract Archive

Upadacitinib effective in treatment of ankylosing spondylitis pts refractory to biologic tx - phase 3 trial Primary endpoint (ASAS40) and secondary endpoints met No malignancy, MACE, VTE, death @RheumNow #EULAR2022 ABST#POS0306 https://t.co/UL4hUJ0rQV

Another possible Rx for #SLE: Phase Ib/IIa orelabrutinib (irrevers BTKi) for SLE shows promise. Improvement in SRI-4, SLEDAI2K, proteinuria, dsDNA, C3/C4; dec in IgG/M/Bcells. Safety: lymphopenia w/ORE #EULAR2022 LB0005 @rheumnow https://t.co/etZ9hMYNfn

#EULAR2022 POS0280 Gout is associated with higher mortality in Women ⭐️Higher all cause and CV mortality RR 1.28 risk of mortality in pts without CHD, with gout compared to controls (No CHD or gout) @Rheumnow https://t.co/6o1EKSp2F8

MIVAC I & II RCTs from India: for AZ vaccine (ChAdOx1), withhold MTX for 2w after: hold both dose 1&2 or hold just dose 2 (vs continue) Endpoint: Ab titre both hold approaches better than continue, to a similar magnitude - similar to German study w mRNA #EULAR2022 @RheumNow

Orelabrutinib Bruton’s tyrosine kinase inhibitor in SLE RCT phase Ib/IIa SRI(4) wk 12 50mg 50% 80mg 61% and 100mg 64% and 37.5% PBO Trend ⬇️ proteinuria, anti-dsDNA & IgG Safety: 3SAEs in OLE group LB0005 @RheumNow #EULAR2022 https://t.co/4r16NTaZvT

Sreekanth et al. 2 studies re holding MTX after both doses vs only 2nd dose of AZ COVID vaccine. Either holding strategy increased ab titres. Only holding 2nd non-inferior to holding both with decreased flares @RheumNow #EULAR2022 LB0003 https://t.co/aCOEdXp4ol https://t.co/XAZyBojryK

• EULAR Abstract Archive

#EULAR2022 LB0006 SAPHYR: P3 trial, 52 wk: Sarilumab in relapsing PMR Study terminated early due to COVID recruitment ⭐️Sustained remission: 28 vs 10%, primary endpt ⭐️HR of flare 0.56 on Sarilumab ⭐️Less steroid usage, glucocorticoid tox score @Rheumnow https://t.co/5PP1YP7YtU

#LB0006 #EULAR2022 Therapy for relapsing polymyalgia rheumatica. 118/280 recruited re:COVID impact. Phase 3 RCT of Sarilumab+14Wk Steroid taper showed more pts had sustained remission at Wk52 vs PBO+52Wk Steroid Taper(28% vs 10%) even if CRP excluded. PRO improved too! @RheumNow https://t.co/P11iXIAfGn

ECLIPSE UK primary care dataset: 23 million pts @DrMaxYates1 1. in >55yo, PMR prevalence 2.2% (10,000 new dx/y) 2. 1/4 take PNL for >4y (PMR = 18% of all pts on PNL) 3. mean 3.5 comorbid dx (steroids worsen) Now tell me we don't need better PMR therapies. #EULAR2022 @RheumNow

Does treating spondyloarthritis early matter? Systematic review showed in nr-axSpA tx with biologics may lead to better outcomes compared to established axSpA axSpA - no difference in response between early vs. established disease @RheumNow #EULAR2022 ABST#POS0302

#EULAR2022 LB003: W/d MTX w COVID vax MIVAC 1: hold MTX both vax vs continuing MIVAC 2: hold after 2nd dose only vs continuing ⭐️MTX hold: improved Ab titers, no diff in MIVAC1/2 ⭐️Higher reported flare for holding with both doses (36%) vs just 2nd dose (12%) @Rheumnow